Tumor mutations and immune activity may reveal who benefits from investigational lymphoma drug
Researchers at the University of Tsukuba conducted a physician-initiated phase 2 clinical trial of dasatinib in patients with relapsed or refractory T-follicular helper cell lymphoma (TFHL), an aggressive and difficult-to-treat blood cancer. The study identified genetic alterations and features of the immune microenvironment associated with treatment response. These findings may help identify…
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
How psychedelics could deliver antidepressant benefits without hallucinogenic effects
Health
Medicine
Global
-
Known for preventing cancer, p53 could also help immune cells fight it
Science
Research
Global
-
How insurance coverage shapes access to kidney transplantation
Health
Medicine
Global
-
Spinal cord injury can reshape gut microbes that influence whole-body health
Science
Biology
-
ASN: Low protein intake linked to kidney failure risk in Asian patients with CKD
Health
Medicine
-
When things go bump in the night: How our brains trick us into hearing things that aren't there
Health
Mental Health
-
Common gut virus infects bacteria—not human cells
Science
Biology
-
Residential fine particulate matter linked to minimal residual disease in pediatric leukemia
Health
Medicine